Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

S. Yao, L. E. Sucheston, H. Zhao, W. E. Barlow, G. Zirpoli, S. Liu, H. C F Moore, G. Thomas Budd, D. L. Hershman, W. Davis, G. L. Ciupak, J. A. Stewart, C. Isaacs, Timothy James Hobday, M. Salim, G. N. Hortobagyi, J. R. Gralow, R. B. Livingston, K. S. Albain, D. F. Hayes & 1 others C. B. Ambrosone

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and treated with cyclophosphamide and doxorubicin. A two-SNP haplotype in ALDH1A1 was associated with an increased risk of grade 3 and 4 hematological toxicity (odds ratio=1.44, 95% confidence interval=1.16-1.78), which remained significant after correction for multiple comparisons. In addition, four SNPs in ABCC1 were associated with gastrointestinal toxicity. Our findings provide evidence that SNPs in pharmacokinetic genes may have an impact on the development of chemotherapy-related toxicities. This is a necessary first step toward building a clinical tool that will help assess risk of adverse outcomes before undergoing chemotherapy.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalPharmacogenomics Journal
Volume14
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Single Nucleotide Polymorphism
Breast Neoplasms
Doxorubicin
Cyclophosphamide
Pharmacokinetics
Drug Therapy
Haplotypes
Genes
Odds Ratio
Confidence Intervals

Keywords

  • ALDH1A1
  • breast cancer
  • chemotherapy
  • pharmacogenetics
  • pharmacokinetics
  • toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. / Yao, S.; Sucheston, L. E.; Zhao, H.; Barlow, W. E.; Zirpoli, G.; Liu, S.; Moore, H. C F; Thomas Budd, G.; Hershman, D. L.; Davis, W.; Ciupak, G. L.; Stewart, J. A.; Isaacs, C.; Hobday, Timothy James; Salim, M.; Hortobagyi, G. N.; Gralow, J. R.; Livingston, R. B.; Albain, K. S.; Hayes, D. F.; Ambrosone, C. B.

In: Pharmacogenomics Journal, Vol. 14, No. 3, 2014, p. 241-247.

Research output: Contribution to journalArticle

Yao, S, Sucheston, LE, Zhao, H, Barlow, WE, Zirpoli, G, Liu, S, Moore, HCF, Thomas Budd, G, Hershman, DL, Davis, W, Ciupak, GL, Stewart, JA, Isaacs, C, Hobday, TJ, Salim, M, Hortobagyi, GN, Gralow, JR, Livingston, RB, Albain, KS, Hayes, DF & Ambrosone, CB 2014, 'Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer', Pharmacogenomics Journal, vol. 14, no. 3, pp. 241-247. https://doi.org/10.1038/tpj.2013.32
Yao, S. ; Sucheston, L. E. ; Zhao, H. ; Barlow, W. E. ; Zirpoli, G. ; Liu, S. ; Moore, H. C F ; Thomas Budd, G. ; Hershman, D. L. ; Davis, W. ; Ciupak, G. L. ; Stewart, J. A. ; Isaacs, C. ; Hobday, Timothy James ; Salim, M. ; Hortobagyi, G. N. ; Gralow, J. R. ; Livingston, R. B. ; Albain, K. S. ; Hayes, D. F. ; Ambrosone, C. B. / Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. In: Pharmacogenomics Journal. 2014 ; Vol. 14, No. 3. pp. 241-247.
@article{54d9393a2dc44fde9aa3ab344cbc3a40,
title = "Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer",
abstract = "Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and treated with cyclophosphamide and doxorubicin. A two-SNP haplotype in ALDH1A1 was associated with an increased risk of grade 3 and 4 hematological toxicity (odds ratio=1.44, 95{\%} confidence interval=1.16-1.78), which remained significant after correction for multiple comparisons. In addition, four SNPs in ABCC1 were associated with gastrointestinal toxicity. Our findings provide evidence that SNPs in pharmacokinetic genes may have an impact on the development of chemotherapy-related toxicities. This is a necessary first step toward building a clinical tool that will help assess risk of adverse outcomes before undergoing chemotherapy.",
keywords = "ALDH1A1, breast cancer, chemotherapy, pharmacogenetics, pharmacokinetics, toxicity",
author = "S. Yao and Sucheston, {L. E.} and H. Zhao and Barlow, {W. E.} and G. Zirpoli and S. Liu and Moore, {H. C F} and {Thomas Budd}, G. and Hershman, {D. L.} and W. Davis and Ciupak, {G. L.} and Stewart, {J. A.} and C. Isaacs and Hobday, {Timothy James} and M. Salim and Hortobagyi, {G. N.} and Gralow, {J. R.} and Livingston, {R. B.} and Albain, {K. S.} and Hayes, {D. F.} and Ambrosone, {C. B.}",
year = "2014",
doi = "10.1038/tpj.2013.32",
language = "English (US)",
volume = "14",
pages = "241--247",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

AU - Yao, S.

AU - Sucheston, L. E.

AU - Zhao, H.

AU - Barlow, W. E.

AU - Zirpoli, G.

AU - Liu, S.

AU - Moore, H. C F

AU - Thomas Budd, G.

AU - Hershman, D. L.

AU - Davis, W.

AU - Ciupak, G. L.

AU - Stewart, J. A.

AU - Isaacs, C.

AU - Hobday, Timothy James

AU - Salim, M.

AU - Hortobagyi, G. N.

AU - Gralow, J. R.

AU - Livingston, R. B.

AU - Albain, K. S.

AU - Hayes, D. F.

AU - Ambrosone, C. B.

PY - 2014

Y1 - 2014

N2 - Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and treated with cyclophosphamide and doxorubicin. A two-SNP haplotype in ALDH1A1 was associated with an increased risk of grade 3 and 4 hematological toxicity (odds ratio=1.44, 95% confidence interval=1.16-1.78), which remained significant after correction for multiple comparisons. In addition, four SNPs in ABCC1 were associated with gastrointestinal toxicity. Our findings provide evidence that SNPs in pharmacokinetic genes may have an impact on the development of chemotherapy-related toxicities. This is a necessary first step toward building a clinical tool that will help assess risk of adverse outcomes before undergoing chemotherapy.

AB - Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and treated with cyclophosphamide and doxorubicin. A two-SNP haplotype in ALDH1A1 was associated with an increased risk of grade 3 and 4 hematological toxicity (odds ratio=1.44, 95% confidence interval=1.16-1.78), which remained significant after correction for multiple comparisons. In addition, four SNPs in ABCC1 were associated with gastrointestinal toxicity. Our findings provide evidence that SNPs in pharmacokinetic genes may have an impact on the development of chemotherapy-related toxicities. This is a necessary first step toward building a clinical tool that will help assess risk of adverse outcomes before undergoing chemotherapy.

KW - ALDH1A1

KW - breast cancer

KW - chemotherapy

KW - pharmacogenetics

KW - pharmacokinetics

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84901268453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901268453&partnerID=8YFLogxK

U2 - 10.1038/tpj.2013.32

DO - 10.1038/tpj.2013.32

M3 - Article

VL - 14

SP - 241

EP - 247

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -